Expanding Treatment Options for Metastatic Breast Cancer

EP. 1: Treatment After Progression on CDK 4/6i in mBC

April 22nd 2020

EP. 2: SOLAR-1 Trial in Metastatic Breast Cancer

April 22nd 2020

EP. 3: Payer Perspective of Coverage on Cancer Therapies

April 22nd 2020

EP. 4: Payer Coverage on Repeat Biopsy in mBC

April 22nd 2020

EP. 5: Advantages of Oral Taxanes in mBC

April 22nd 2020

EP. 6: Compliance and Adherence to Therapy in mBC

April 22nd 2020

EP. 7: Payer Coverage of IV Versus Oral Therapy in mBC

April 22nd 2020

EP. 8: Evolving Treatment Landscape of R/R HER2+ mBC

April 22nd 2020

EP. 9: HER2CLIMB and NALA Trials: R/R HER2+ mBC

April 22nd 2020

EP. 10: SOPHIA Trial in R/R HER2+ mBC

April 22nd 2020

EP. 11: Sequencing of Therapy in R/R HER2+ mBC

April 22nd 2020

EP. 12: IMpassion130 Trial Data on PD-L1+ Tumors in TNBC

April 22nd 2020

EP. 13: Role of PARP Inhibition and I/O Therapy in TNBC

April 22nd 2020

EP. 14: Treatment Options in Metastatic TNBC

April 22nd 2020

EP. 15: Considerations for NGS Testing in mTNBC

April 22nd 2020

EP. 16: Assessing the Value of Personalized Treatment in mBC

April 22nd 2020

EP. 17: Closing Thoughts on Metastatic Breast Cancers

April 22nd 2020